An inquest in Berkshire has linked the suicide of lawyer Alexander Mulroney to the antibiotic ofloxacin. Assistant Coroner Ian Wade KC found that the medication induced a fatal determination in the man,who had no prior history of mental health issues.
The psychiatric risks linked to the fluoroquinolone class
The case of Mr. Mulroney highlights a broader, recurring issue involving the fluoroquinolone class of antibiotics. while these medications are widely used and beneficial for treating various infections, they have been associated with unexpected psychological side effects in patients who previously showed no signs of emotional or mental instability.
Alexander Mulroney, described as an intelligent and successful legal professional, had a stable life and a secure relationship with his wife and children. According to findings presented at an inquest in Berkshire, the medication did not physically cause his death but instead induced a "fatal determination" to end his life. This pattern of sudden psychological shifts in otherwise healthy individuals is a concern that the coroner noted is not an isolated incident.
Alexander Mulroney’s final days in Reading
Alexander Mulroney’s medical complications began in mid-December 2025. On December 16, 2025, he was prescribed ofloxacin to treat persistent urinary and genital symptoms after a first-line antibiotic failed to resolve his physical condition.
The timeline of events grew tragic on the evening of December 17,when Mr. Mulroney left his home in Reading. While he informed his wife he was seeking hospital treatment for a rash, the inquest revealed his primary distress was actually psychological. After an initial attempt to end his life from within his car,he died in the early hours of December 18.
A Prevention of Future Deaths report for the MHRA and NICE
Assistant Coroner Ian Wade KC has issued a Prevention of Future Deaths report to prompt an immediate review of prescribing practices. This formal report is directed at major healthcare authorities, including the Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence (NICE).
The coroner’s findings also implicate the British National Formulary in the need for updated safety information. As reported by the coroner,the current regulatory approach to publishing warnings about potential harm provides insufficient safeguards for both medical prescribers and the patients they treat.
What remains unaddressed in the MHRA's warning protocols?
While the coroner has called for systemic changes, several specifics regarding the regulatory response remain unverified. It is not yet clear how the MHRA intends to restructure its communication strategy to ensure that warnings are adequately understood by the public. Additionally, the inquest did not clarify whether the failure in this case was the specific choice of ofloxacin over other antibiotics, or a lack of psychiatric monitoring following the initial dose.
Comments 0